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ABSTRACT 
Objectives: The purpose of this prospective, randomized, single-blinded, 
placebo-controlled study is to compare radiofrequency ablation, diode laser, and 
microdebrider-assisted inferior turbinoplasty techniques in the treatment of chronic nasal 
obstruction caused by inferior turbinate enlargement, and to compare these techniques 
with a placebo procedure. 
Methods: A total of 98 consecutive patients with enlarged inferior turbinates due to 
persistent year-round rhinitis were randomized into a placebo, radiofrequency ablation, 
diode laser, and microdebrider-assisted inferior turbinoplasty groups in a ratio of 1:2:2:2. 
All the procedures were carried out under local anesthesia with the patients’ eyes covered. 
Assessments were conducted prior to surgery and three months subsequent to the 
surgery. 
Results: The severity of nasal obstruction measured by VAS score decreased statistically 
significantly in all the groups, including placebo. Radiofrequency ablation (p = 0.03), diode 
laser (p = 0.02), and microdebrider-assisted inferior turbinoplasty (p = 0.04) all decreased 
the symptom score of the severity of nasal obstruction statistically significantly more 
compared to the placebo procedure. 
Conclusion: The placebo effect had a large role in the overall improvement of the severity 
of nasal obstruction after the inferior turbinate surgery. However, all three techniques 
provided a statistically significant additional reduction of the severity of nasal obstruction 
compared to the placebo procedure. 
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INTRODUCTION 
Inferior turbinate enlargement due to persistent year-round allergic or non-allergic rhinitis is 
one of the main causes of chronic nasal obstruction.1 Intranasal corticosteroids are the 
most important medicine group in the treatment of rhinitis and hypertrophied inferior 
turbinates. When medical therapy for enlarged inferior turbinates fails, turbinate surgery 
can be considered.2 
 
Various surgical techniques have been described for the reduction of hyperplastic inferior 
turbinates. However, no clear consensus exists in the literature on the exact role of 
surgery or the most optimal method for surgical treatment.3 In recent years, surgical 
procedures have concentrated on the minimal disturbance of the nasal mucosa. The aim 
of inferior turbinate surgery has been to maximize the volumetric reduction of the turbinate 
to decrease the nasal obstruction while maintaining nasal function and minimizing 
complications.4   
 
Microdebrider-assisted inferior turbinoplasty (MAIT) – a powered subtype of submucosal 
resection5 – and radiofrequency ablation (RFA) are referred to as mucosal sparing 
techniques; they are widely used and the most commonly studied techniques in the recent 
literature.4 The diode laser technique has also gained in popularity due to its ease of use in 
the office setting.6 
 
Thus far, three placebo-controlled trials have been published regarding RFA. These 
studies have evaluated the influence of the treatment on subjective scores of nasal 
obstruction, and they found that the placebo effect seems to have a role in the results of 
turbinate surgery.7,8,9  
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The purpose of this prospective, randomized, single-blinded, placebo-controlled study is to 
compare RFA, diode laser, and MAIT techniques in the treatment of chronic nasal 
obstruction caused by inferior turbinate enlargement, and to compare these techniques 
with a placebo treatment. 
 
 
METHODS 
This prospective randomized study was carried out at Tampere University Hospital, 
Tampere, Finland, between February 2014 and September 2017. The institutional review 
board approved the study design (R13144) and all patients provided written, informed 
consent. A total of 98 consecutive adult patients with enlarged inferior turbinates due to 
persistent year-round rhinitis were enrolled in this study. The patients presented symptoms 
of bilateral nasal obstruction related to inferior turbinate congestion that had not 
responded to a three-month trial of appropriate treatment with intranasal corticosteroids. 
Patients with significant nasal septum deviation affecting the nasal valve region, 
internal/external valve collapse/stenosis, chronic rhinosinusitis with or without polyposis, 
previous nasal surgery, sinonasal tumor, severe systemic disorder, severe obesity, or 
malignancy were excluded.  
 
Cone beam computed tomography (Planmeca Max, Planmeca, Helsinki, Finland) was 
used to exclude patients with chronic rhinosinusitis from the study. Serum-specific IgE 
level measurements were used to identify the patients with an allergic sensitization. 
Allergic sensitization was defined as a specific IgE > 0.35 for any common airborne 
allergen (cat, dog, horse, birch, grass, mugwort, D. pteronyssinus, and molds). 
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The definition of inferior turbinate enlargement was based on persistent bilateral 
symptoms, a finding of bilateral swelling of the inferior turbinate in nasal endoscopy, and 
the evident shrinking of both turbinates in a decongestion test, which could not be applied 
to either bony turbinate enlargement of soft tissue hypertrophy unresponsive to topical 
decongestant. The nasal response to the topical vasoconstrictor 0.5% xylometazoline 
hydrochloride (Nasolin, Orion, Finland) in both nasal cavities 15 minutes before obtaining 
the second measurement was evaluated objectively using acoustic rhinometry (Acoustic 
rhinometer A1, GM instruments Ltd, Kilwinning, UK). An improvement of less than 30% 
in anterior nasal cavity volume (V2–5 cm) in one or both nasal cavities 
was considered normal and those patients were excluded from the study. The limit value 
of 30% was chosen according to previous literature.10,11,12 
 
Patients were consecutively randomized into placebo, RFA, diode laser, and MAIT groups 
in a ratio of 1:2:2:2 using Minim, a free MS-DOS program that randomizes patients to 
treatment groups by the method of minimization. Proportional amounts of patients with 
allergic sensitization were kept similar for each group. Age and sex distributions were also 
kept similar for each group.  
 
The surgical treatment was performed in similar circumstances at the day surgery 
department of the hospital's ENT clinic. All surgical procedures were performed by the 
same surgeon (T.H). The staff of the day surgery department was instructed to avoid all 
communication before and during the operation, as well as during the post-operative care, 
that might reveal the group of the patient. All the alternative surgical devices were 
available in the operation room. The procedures were carried out under local anesthesia 
with the patient's eyes covered.  
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First, the inferior turbinate was topically anesthetized using cotton strips with a mixture of 
lidocaine 40mg/ml (Lidocain, Orion, Finland) and 2–3 drops of epinephrine 0.1% in 5–10 
ml of lidocaine. 1.5 ml of local anesthetic (Lidocain 10mg/ml c. adrenalin 10µg/ml, Orion, 
Finland) was then applied to the medial portions of both inferior turbinates. All the 
procedures were performed under the direct vision of a straight, 4 mm-diameter, 0-degree 
endoscope (Karl Storz, Germany). In all the groups with every technique, the treatment 
was given to the medial side of the anterior half of the inferior turbinate. Short-term (until 
next morning) nasal packing with non-absorbable packing material (Ivalon, Fabco, New 
London, Connecticut) was applied only if active bleeding developed during the surgery. 
 
The RFA treatment was carried out with a radiofrequency generator (Sutter RF generator 
BM-780 II). A “Binner” bipolar needle electrode was inserted into the medial submucosal 
tissue of the inferior turbinate. The upper and lower parts of the anterior half of the inferior 
turbinate were treated for 6 sec at 10W output power in three areas.  
 
The diode laser treatment was given with a FOX Laser (A.R.C. LASER GmbH, 
Nuremberg, Germany). The settings were as follows: wavelength of 980 nm, output power 
of 6 W in continuous-wave mode, and laser delivery by a 600 µm fiber using “contact” 
mode. Four parallel stripes were made on the mucosa by drawing the fiber from the 
posterior to the anterior direction along the medial edge of the anterior half of the inferior 
turbinate. 
 
In the MAIT treatment, a 2.9 mm-diameter rotatable microdebrider tip (Medtronic Xomed, 
Jacksonville, Florida) was firmly pushed toward the turbinate bone until it pierced the 
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mucosa of the anterior face of the inferior turbinate. Next, a submucosal pocket was 
dissected by tunneling the elevator tip in an anterior-to-posterior and superior-to-inferior 
sweeping motion. Once an adequate pocket had been created, resection of the stromal 
tissue was carried out by moving the blade back and forth in a sweeping motion, with the 
system set at 3000 rpm using suction irrigation. 
 
In the placebo procedure, small (2-3 mm in diameter) nasal mucosal biopsies were first 
taken from the anterior medial portions of the inferior turbinates, causing minor bleeding. 
Next, a radiofrequency tissue ablation device was turned on repeatedly near the patient, 
but without the needle electrodes of the device touching the patient; the patient could only 
hear the acoustic tone of the device. During this sound deception, a suction tube and a 
nasal endoscope were moved lightly in both sides of the nose for a couple of minutes in 
order to convince the patients that they had undergone surgery. 
 
After the operation, none of the patients were given medical treatment, including 
analgesics, nasal steroids and nasal decongestants. The patients were given a 100 mm 
visual analogue scale (VAS) questionnaire, which had been filled for the first time during 
the preoperative visit. They were asked to mark on the line the point that they feel 
represents their perception of their current state regarding post-operative nasal symptoms, 
including severity of nasal obstruction (not obstructed – very obstructed), discharge (no 
discharge – much discharge), crusting (no crust – much crust), and pain (no pain – much 
pain). The questionnaire was to be filled daily for the first week, and then after two, three 
and four weeks post-operatively. They were instructed to return the questionnaire by post 
one month after the operation. 
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All the patients were evaluated prior to surgery and three months subsequent to the 
surgery. All clinical examinations were performed by the same examiner (T.H) who was 
also the operator and not blinded to the patients’ group. The patients filled the VAS 
questionnaire regarding nasal symptoms during both visits. They were asked to mark on 
the line the point that they feel represents their perception of their current state. Acoustic 
rhinometry was also performed both before the surgery and during the control visit at three 
months. During the control visit, the patients filled the questionnaire before meeting the 
examiner.  
 
IBM SPSS Statistics 22.0 was used for the statistical analyses. All non-parametric data 
were statistically processed using the Wilcoxon signed-rank test, Mann–Whitney U test, 
and Kruskal–Wallis test. In the cases with parametric data, the comparison between the 
groups was carried out by one-way ANOVA. 
 
 
RESULTS 
The patients' characteristics are described in Table 1 and the data of the operations in 
Table 2. The operation time for the MAIT procedure was statistically significantly longer 
compared to the other procedures. The operation time for the diode laser, in turn, was 
statistically significantly longer than the time for the RFA. The VAS score for pain during 
the operation was highest in the MAIT group, but there were no statistically significant 
differences between the groups. Five patients in the MAIT group and one patient in the 
diode laser group had moderate bleeding that required short-term (until next morning) 
nasal packing. Four patients in the MAIT group complained of notable bleeding during the 
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first post-operative day and three of them had to be treated at the outpatient clinic with 
short-term (until next morning) nasal packing. 
 
The changes in nasal symptoms reported by the patients after the operation are described 
in Figure 1 (A–D). The severity of nasal obstruction started to decrease immediately after 
MAIT and continued up to four weeks. In the diode laser and RFA groups, the response 
appeared slightly slower. In the placebo group, the response also started immediately and 
reached its final level after two weeks.  
 
At the control visit at three months, minor crusting was seen in the nasal cavities of a 
single patient in the placebo group, in 12 patients in the RFA group, in six patients in the 
diode laser group, and in two patients in the MAIT group. One patient in the MAIT group 
had a small synechia. Atrophy was not found in any of the cases. 
 
The changes in the VAS scores for nasal symptoms at three months are described in 
Table 3. The severity of nasal obstruction decreased statistically significantly in all the 
groups. All the techniques used were compared separately with placebo using the Mann–
Whitney U test. RFA (p = 0.02), diode laser (p = 0.03), and MAIT (p = 0.04) all decreased 
the symptom score for the severity of nasal obstruction statistically significantly more 
compared to the placebo procedure.  
 
In all the groups, nasal discharge and crusting decreased statistically significantly, but 
there were no statistically significant differences between the groups, including the placebo 
group (Table 3). 
 
10 
 
 
The change in V2–5 cm acoustic rhinometry values is described in Table 4. All three 
techniques improved the V2–5 cm values significantly, but there were no statistically 
significant differences between the groups, including placebo. 
 
 
DISCUSSION 
There are studies reporting notable intraoperative bleeding13 or post-operative bleeding in 
the early days after MAIT,14 and this was also the case in the present study. During the 
operation, the mean VAS score for pain was the highest in the MAIT group, but there was 
no statistical difference between the groups. Post-operatively, there was an increase in the 
VAS score for pain in the MAIT group, which lasted up to one week. This can possibly be 
explained by the direct surgical tissue trauma caused by the operation. Short-term nasal 
packing, which was most common in the MAIT group, may also partly explain the increase 
of pain during the first days of the follow-up. Increased pain was also reported during the 
first two days after diode laser treatment. This can possibly be explained by the higher 
temperature and therefore the more severe tissue damage caused by the laser compared 
to the RFA. In the present study, a temporary increase in the symptom of nasal discharge 
and a minor increase in the symptom of crusting during the first post-operative days after 
RFA was noted. A similar finding has been reported in the previous studies.15,16 Some 
patients treated with RFA complained of crust formation for as long as three months. In a 
study by Janda et al., patients showed moderate-to-severe nasal obstruction, crusting, and 
nasal secretion in the first four weeks following diode laser treatment.6 In the present 
study, however, patients in the diode laser group on average reported a decrease in 
crusting immediately after the operation and an increase in nasal discharge only during the 
first two days. In some cases, however, crust formation continued up to three months. 
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In recent years, studies have been published comparing RFA and MAIT in the treatment of 
nasal obstruction. There are studies where the results of MAIT have been better in the 
short follow-up14 and also in the longer follow-up.17 There are also studies where the 
techniques have been found equal in efficacy.18 A systematic review and meta-analysis by 
Acavedo et al. compared RFA and MAIT. They concluded that inferior turbinate reduction 
produces a significant subjective and objective improvement in nasal airflow in the short 
term, which is not related to the technique used.19 There are also studies comparing RFA 
and the diode laser20,21 and MAIT and the diode laser,13 and no significant differences 
between the techniques have been found in any of these studies. No previous studies 
have compared all three techniques together. 
 
In the present study, the decrease in the VAS score for severity of nasal obstruction 
started faster after MAIT. In MAIT, the submucosa of the turbinate is emptied immediately 
during the operation, whereas in the RFA and diode laser procedures, the heat caused by 
the device creates a submucosal lesion, inducing scarring and tissue volume reduction 
during the following weeks.1,22 Post-operative nasal packing, which was most common in 
the MAIT group, squeezes the mucosa of the emptied turbinate against the bone and may 
so contribute to the faster response. Based on this conclusion and the higher rate of post-
operative bleeding in the MAIT group, nasal packing can be recommended in the MAIT 
procedures. At the end of the three-month follow-up, all three techniques decreased the 
VAS score for the severity of nasal obstruction and V2–5 cm values statistically 
significantly compared to the preoperative values, and they were equal in efficacy 
regarding both parameters.  
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So far, there have been only three placebo-controlled trials evaluating the influence of the 
treatment on the subjective scores of nasal obstruction. In a double-blinded, 
placebo-controlled trial by Powell et al., 22 patients were randomly assigned to either an 
RFA (n = 17) or placebo (n = 5) group. The beneficial effect of treatment on nasal 
obstruction with RFA was demonstrated, but it did not reach statistical significance, 
probably due to the small sample size.7 A single-blinded, placebo-controlled trial with a 
crossover option by Nease et al. included 32 patients who were randomized to either an 
RFA (n = 16) or placebo (n = 16) group. Improvement was shown in the frequency of nasal 
obstruction, severity of nasal obstruction, and overall ability to breathe for both the placebo 
and RFA treatment arms at 8 weeks. However, the effects of RFA were significantly better 
than those of placebo in the severity of nasal obstruction and overall ability to breathe.8 In 
a single-blinded, placebo-controlled, crossover trial by Bran et al. with 22 patients, the first 
group received RFA first followed by a placebo treatment 6–8 weeks later. In the second 
group, the order was reversed. Nasal obstruction decreased significantly only after RFA in 
both groups. There was a tendency of improvement after placebo in both treatment arms. 
However, the observed trends of a placebo effect were not statistically significant.9 
 
Our study is the first placebo-controlled study involving three different techniques, and also 
the first study where the diode laser and MAIT have been compared with placebo 
treatment. The follow-up time of three months with the placebo group is also the longest so 
far. RFA, diode laser, and MAIT all improved the VAS score for the severity of nasal 
obstruction statistically significantly better than placebo. The finding is in line with the study 
by Nease et al. regarding RFA.8 The true treatment effect is the difference in improvement 
between the intervention group and the control group (placebo effect).7 In the present 
study, the mean true treatment effect in the VAS score change was found to be -2.1 for all 
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three techniques. The placebo effect accounted for a large part of the total improvement 
seen in the intervention groups. Without a placebo control, we would have falsely found a 
greater improvement and significance due to treatment.  
 
In the present study, all the techniques decreased the symptom scores of nasal discharge 
and crusting statistically significantly compared to the preoperative values at the end of the 
three-month follow-up, but none of them statistically significantly compared to placebo. In 
addition, minor crusting was still found in some noses at three months, especially in the 
RFA and diode laser groups. Therefore, the major part of the improvement of these 
symptoms can be explained by the placebo effect.  
 
Anterior nasal cavity volume (V2–5 cm) in acoustic rhinometry was used as a parameter 
for objective examination. It represents well the operated anterior half of the inferior 
turbinate. Acoustic rhinometry will give a valid result in most instances, at least for the first 
5–6 cm of the nasal cavity.23 Measurement of V2–5 cm is the most sensitive measurement 
for change in mucosal swelling during decongestion,24 and that is why the parameter also 
had an important role in the preoperative decongestion test in defining inferior turbinate 
enlargement. In the three-month follow-up, RFA, diode laser and MAIT techniques all 
improved the V2–5 cm values statistically significantly compared to the preoperative 
values. Due to lack of a real surgical procedure, there was understandably no statistically 
significant change in the V2-5 cm values in the placebo group. This supports the 
conclusion that the improvement in the VAS score for severity of nasal obstruction in the 
placebo group was due to placebo effect. However, none of the techniques improved the 
volume statistically significantly compared to placebo. This finding can be partly explained 
by the relatively small number of patients in the placebo group. A larger number might 
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have led to a statistical significance. In addition, environmental conditions and technical 
difficulties in measurement may have an influence in the volume values.25 Furthermore, 
the symptom of nasal obstruction and objective parameters do not always correlate very 
well.26 On the other hand, it is wise to remember that the increase in the nasal cavity 
volume should be optimal instead of too large in order to avoid making the nose too wide, 
which might lead to problems such as nasal dryness, crusting, atrophy, worsening of the 
symptom of nasal obstruction, and "empty nose syndrome".1,27 
 
 
CONCLUSION 
After three months’ follow-up, there were no statistically significant differences between the 
examined techniques in their efficacy in treating nasal obstruction. Possible differences in 
their efficacy may emerge in the long term. Therefore, more studies comparing these 
techniques with longer follow-ups are needed.  
 
RFA, diode laser, and MAIT were all genuinely effective in treating chronic nasal 
obstruction caused by inferior turbinate enlargement. The placebo effect had a large role in 
the overall reduction of the severity of nasal obstruction after the inferior turbinate surgery, 
but all the three techniques provided a statistically significant additional reduction in the 
severity of nasal obstruction compared to the placebo procedure. 
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TABLE I. Patients’ characteristics (N = 98). 
Age, median (range) 46 (19–69) 
Sex  
   Male, No 56 
   Female, No 42 
Group, No  
   Placebo 14  
      Allergic sensitization    
         Yes, No (%) 6 (43) 
         No, No (%) 8 (57) 
   RFA 28  
      Allergic sensitization    
         Yes, No (%) 12 (43) 
         No, No (%) 16 (57) 
   Diode laser 28 
      Allergic sensitization    
         Yes, No (%) 12 (43) 
         No, No (%) 16 (57) 
   MAIT 28 
      Allergic sensitization  
         Yes, No (%) 13 (46) 
         No, No (%) 15 (54) 
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TABLE II. Comparison of operation time, pain during the operation, and bleeding of the groups. 
 Time (s (95% CI)) Pain (VAS (95% CI)) Nasal packing 
needed (No) 
Post-operative 
bleeding (No) 
Post-operative 
bleeding requiring 
treatment (No) 
Group      
   Placebo 186 (167–205) 1.4 (0.6–2.1) 0 0 0 
   RFA 217 (194–240) 2.4 (1.6–3.1) 0 1 0 
   Diode laser 374 (329–420) 2.3 (1.6–3.1) 1 0 0 
   MAIT 545 (508–583) 2.9 (2.1–3.6) 5 4 3 
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TABLE III. Change in the VAS scores for nasal symptoms at three months. 
 Placebo RFA Diode laser MAIT p-value† 
Severity of obstruction, 
median (IQR) 
     
  Preoperative 7.0 (5.8–8.0) 8.0 (6.3–8.9) 8.0 (7.0–8.0) 8.0 (7.0–9.0) NS 
  Post-operative  4.0 (2.0–6.3) 2.0 (1.0–3.8) 3.0 (1.6–4.0) 3.0 (1.6–4.0)  
  Change, median -2.5 (-5.0–-0.8) -5.0 (-7.0–-3.3) -5.0 (-6.0–-3.0) -5.5 (-6.4–-3.0) 0.04* 
  Change, mean (95% CI) -2.6 (-4.0–-1.3) -4.7 (-5.6–-3.8) -4.7 (-5.4–-4.0) -4.7 (-5.7–-3.7)  
  p-value‡ 0.004* <0.001* <0.001* <0.001*  
  Change compared to   
  placebo, mean (95% CI)   
  
-2.1 (-4.0–-0.1) 
 
-2.1 (-4.0–0.1) 
 
-2.1 (-4.1–-0.1) 
 
  p-value§  0.03* 0.02* 0.04*  
      
Discharge, median (IQR)      
  Preoperative 3.5 (1.8–5.3) 6.0 (2.3–7.8) 5.5 (3.3–7.0) 5.0 (3.3–7.0) NS 
  Post-operative 2.0 (0.9–3.0) 2.0 (0.0–4.8) 2.0 (1.0–4.1) 2.0 (1.0–4.5)  
  Change, median  -1.5 (-4.0–- 0.3) -2.0 (-5.0–-0.6) -2.5 (-4.0–-1.0) -2.0 (-4.8–-0.4) NS 
  p-value‡ 0.06 <0.001* <0.001* 0.001*  
      
Crust, median (IQR)      
  Preoperative  4.6 (3.0–6.3) 5.4 (4.6–6.3) 5.3 (4.6–6.0) 6.0 (5.1–6.8) NS 
  Post-operative  3.1 (1.6–4.6) 3.0 (2.1–3.8) 3.3 (2.4–4.3) 3.0 (2.1–4.0)  
  Change, median -2.0 (-3.3–-0.4) -2.0 (-5.0–-1.0) -2.0 (-3.8–0.0) -3.0 (-4.0–-1.3) NS 
  p-value‡ 0.08 <0.001* <0.001* <0.001*  
  The distribution of the data is non-parametric, hence medians and interquartile ranges (IQR: Q25–Q75) are  
  used in the statistical testing. † Kruskal–Wallis test; ‡ Wilcoxon signed-rank test; § Mann–Whitney U test with  
  Bonferroni correction; NS = not significant; * statistically significant 
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TABLE IV. Change in V2–5 cm acoustic rhinometry values (one side of the nasal cavity). 
 Placebo RFA Diode laser MAIT p-value† 
V2–5 cm (cm3)      
  Preoperative              
     Median (IQR) 3.60 (2.82–4.94) 4.39 (3.02–5.65) 3.47 (2.71 4.36) 3.57 (2.52–4.58) NS 
  Post-operative       
     Median (IQR) 3.94 (2.82–5.33) 5.39 (4.29–6.48) 4.37 (3.56–5.60) 4.27 (3.37–5.41  
  Change      
     Median (IQR) 0.39 (-0.21–0.96) 1.12 (-0.38–2.39) 0.84 (-0.41–1.66) 0.64 (-0.27–1.56) NS 
     Mean (95% CI) 0.13 (-0.51–0.77) 1.14 (0.51–1.78) 0.85 (0.43–1.26) 0.86 (0.30–1.41)  
     p-value‡ NS <0.001* 0.001* 0.003*  
    The distribution of the data is non-parametric, hence medians and interquartile ranges (IQR: Q25–Q75) are 
    used in the statistical testing. † Kruskal–Wallis test; ‡ Wilcoxon signed-rank test; NS = not significant; * statistically 
    significant 
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Figure I. Mean changes in the severity of nasal obstruction (A), discharge (B), crust (C) and pain (D) after the 
operation.  
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